MaxCyte, Inc. (MXCT) — insider trading
Health Care · NASDAQ
MaxCyte, Inc. (MXCT) has 20 reported SEC Form 4 insider transactions in our data (latest 2026-06-17).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-17 | Al-Wakeel Yasir B. | Director | Grant / award / vesting (derivative) | 49,579 | — | $0 | Form 4 |
| 2026-06-17 | Al-Wakeel Yasir B. | Director | Grant / award / vesting | 30,421 | — | $0 | Form 4 |
| 2026-06-17 | BALTHROP PATRICK J | Director | Grant / award / vesting (derivative) | 49,579 | — | $0 | Form 4 |
| 2026-06-17 | BALTHROP PATRICK J | Director | Grant / award / vesting | 30,421 | — | $0 | Form 4 |
| 2026-06-17 | Brooke William W | Director | Grant / award / vesting (derivative) | 49,579 | — | $0 | Form 4 |
| 2026-06-17 | Brooke William W | Director | Grant / award / vesting | 30,421 | — | $0 | Form 4 |
| 2026-06-17 | Collins Cynthia | Director | Grant / award / vesting (derivative) | 49,579 | — | $0 | Form 4 |
| 2026-06-17 | Collins Cynthia | Director | Grant / award / vesting | 30,421 | — | $0 | Form 4 |
| 2026-06-17 | DOUGLAS RICHARD | Director | Grant / award / vesting (derivative) | 49,579 | — | $0 | Form 4 |
| 2026-06-17 | DOUGLAS RICHARD | Director | Grant / award / vesting | 30,421 | — | $0 | Form 4 |
| 2026-06-17 | Erck Stanley C | Director | Grant / award / vesting (derivative) | 49,579 | — | $0 | Form 4 |
| 2026-06-17 | Erck Stanley C | Director | Grant / award / vesting | 30,421 | — | $0 | Form 4 |
| 2026-06-17 | Hemrajani Rekha | Director | Grant / award / vesting (derivative) | 49,579 | — | $0 | Form 4 |
| 2026-06-17 | Hemrajani Rekha | Director | Grant / award / vesting | 30,421 | — | $0 | Form 4 |
| 2026-06-17 | Johnston John Joseph | Director | Grant / award / vesting (derivative) | 49,579 | — | $0 | Form 4 |
| 2026-06-17 | Johnston John Joseph | Director | Grant / award / vesting | 30,421 | — | $0 | Form 4 |
| 2026-04-15 | Ahuja Parmeet | Officer (Chief Financial Officer) | Grant / award / vesting | 187,500 | — | $0 | Form 4 |
| 2026-03-30 | Ahuja Parmeet | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 375,000 | — | $0 | Form 4 |
| 2026-03-27 | Masoud Maher | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 600,000 | — | $0 | Form 4 |
| 2026-03-27 | Masoud Maher | Director, Officer (President and CEO) | Grant / award / vesting | 300,000 | — | $0 | Form 4 |
Ask the chat about MXCT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: MaxCyte, Inc. (MXCT).
Last updated 2026-06-17 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.